Rioux博士于2018年10月加入Certara，现已成为综合药物发展副总裁。Nathalie获得了她的博士学位。在拉瓦尔大学的药房，加拿大魁北克，她在那里学习了非甾体抗炎药和脂氧合酶抑制剂的肺癌化学预防。  Following graduate school, Nathalie completed an industrial post-doctoral fellowship in drug metabolism, sponsored by NSERC Canada/生物化学制药。

Nathalie在Biotech，Pharma和CRO服务中拥有超过15年的制药业经验。  After being a DMPK lab head & project leader for multiple antiviral drug development projects atBoehringher.Ingelheim加拿大，她搬到了一个主要的科学家角色癫痫，她代表了多学科肿瘤学发现和非界限计划的DMPK，包括与GSK，Eisai和Celgene的联盟。  Most recently, she built the DMPK, bioanalytical and clinical pharmacology group at H3 Biomedicine in Cambridge, MA, where she drove the strategic and tactical activities around ADME, PK/TK, bioanalysis, and modeling across the discovery and development space.  At H3, she acted as a member of the development leadership team, where she contributed to regular review of project strategy, selection of development candidate, and multiple due-diligence activities.  Nathalie has co-authored multiple regulatory documents and contributed to several development compounds in H3’s Phase 1/1b oncology program.